14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Nov 29, 2018 $44.70 $46.95 $43.92 $45.77 2 250 040
Nov 28, 2018 $44.50 $44.88 $40.63 $44.74 3 346 157
Nov 27, 2018 $43.42 $47.98 $42.50 $45.42 3 545 851
Nov 26, 2018 $41.92 $44.37 $40.61 $43.96 2 332 317
Nov 23, 2018 $42.30 $44.55 $41.55 $43.01 2 151 441
Nov 21, 2018 $42.56 $43.92 $39.41 $42.88 4 392 023
Nov 20, 2018 $35.60 $43.70 $35.55 $42.48 9 480 197
Nov 19, 2018 $34.93 $39.00 $32.82 $36.83 10 205 105
Nov 16, 2018 $26.46 $38.35 $25.89 $34.96 7 657 241
Nov 15, 2018 $26.10 $27.19 $25.90 $26.59 1 473 203
Nov 14, 2018 $28.99 $29.57 $25.96 $25.99 2 407 189
Nov 13, 2018 $27.27 $29.95 $26.88 $29.29 2 518 238
Nov 12, 2018 $25.11 $27.28 $24.77 $27.01 3 497 626
Nov 09, 2018 $30.73 $32.33 $23.41 $25.10 3 875 651
Nov 08, 2018 $31.46 $32.19 $30.77 $30.91 983 231
Nov 07, 2018 $29.50 $31.61 $29.15 $31.53 1 268 930
Nov 06, 2018 $30.84 $31.25 $29.21 $29.40 1 371 275
Nov 05, 2018 $30.17 $32.00 $29.56 $31.22 1 859 846
Nov 02, 2018 $32.81 $34.36 $29.46 $30.30 3 574 738
Nov 01, 2018 $29.37 $32.05 $28.71 $31.88 1 990 535
Oct 31, 2018 $28.86 $29.50 $27.15 $28.88 2 738 014
Oct 30, 2018 $30.65 $31.63 $30.07 $31.17 1 731 469
Oct 29, 2018 $32.01 $33.32 $30.33 $30.84 1 369 927
Oct 26, 2018 $31.95 $32.57 $30.67 $31.50 1 622 456
Oct 25, 2018 $31.35 $33.12 $30.83 $32.67 2 508 085
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT